Celltrion Says It Has Prepared Contingency Strategies for U.S. Pharmaceutical Tariffs

"Plans to Complete Preparations by the End of Next Year"

Celltrion announced its contingency strategies on July 9 in response to potential U.S. tariffs on pharmaceuticals.

Celltrion

Earlier that day, U.S. President Donald Trump mentioned the possibility of imposing tariffs on pharmaceuticals, with a grace period of up to 18 months.

Celltrion stated that it has been continuously monitoring the U.S. movement toward pharmaceutical tariffs and has prepared contingency plans to minimize the impact.

In the short term, the company has secured a two-year inventory and plans to maintain a rolling two-year stock going forward. In the medium term, Celltrion has finalized contracts with contract manufacturing organization (CMO) partners to enable local production of products sold in the U.S. In the long term, the company is even considering acquiring a company with manufacturing facilities in the U.S.

A Celltrion official said, "We are steadily implementing not only short-term but also mid- and long-term strategies," adding, "We plan to complete preparations by the end of next year so that we are not affected regardless of when or to what extent the U.S. pharmaceutical tariff policy is decided."

The official continued, "We will continue to keep our shareholders updated on related developments to maintain trust and support for the company."